We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Breast Biopsy and Tissue Removal System

By HospiMedica staff writers
Posted on 05 Apr 2005
A breast biopsy system can now be used for partial or complete removal of breast tissue. More...
This new indication has been cleared by the U.S. Food and Drug Administration (FDA).

A biopsy procedure using the Atec system of Suros Surgical Systems, Inc. (Indianapolis, IN, USA), involves a one-time needle insertion in the breast near or at the site where the lump was found. No stitches are required following the biopsy procedure and most women can resume normal daily activity immediately. The Atec Pearl system is used for biopsy guided by ultrasound or x-ray, while the Atec Sapphire can be used with ultrasound, x-ray, or magnetic resonance (MR) imaging. The typical time required for biopsy is less than one minute.

Surgeons have also used Atec to completely remove fibroadenomas up to 4 cm in one step. Women can now have noncancerous breast lumps diagnosed and completely removed in the convenience of their doctor's office without the trauma and disfigurement of invasive surgery or the need for a surgical incision.

"For many years, I have seen women in our practice who remained concerned about a breast lump despite a prior benign diagnosis by needle biopsy,” noted Dr. Jeffrey Mendel, chairman of radiology at Caritas St. Elizabeth Medical Center of Boston (MA, USA). "The only alternative to them was surgical excision. The Atec system allows us to offer these patients and other women with probably benign lesions diagnosis and treatment with a single procedure.”

Suros notes it is the industry leader in MRI-guided breast biopsy with its Atec system, which has been used in more than 3,000 biopsy procedures in more than 100 U.S. centers.




Related Links:
Suros Surgical Systems

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
VTE Prevention System
Flowtron ACS900
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.